Gastroenterology

The approval for moderately to severely active Crohn disease marks the fourth indication for Johnson and Johnson's IL-23 inhibitor.

In the final segment of this 6-part RX Review, experts discuss key concepts from the USMSTF guidance where evidence is limited.

In the fifth segment of this 6-part RX Review, experts discuss areas where more research is needed on bowel preparation for colonoscopy.

In the fourth segment of this 6-part RX Review, experts discuss potential barriers to implementation of the USMSTF guidance and compliance challenges.

In the third segment of this 6-part RX Review, experts discuss key updates from the previous 2014 iteration of the USMSTF guidance.

In the second segment of this 6-part RX Review, experts discuss benchmarks for assessing adequate bowel preparation and the need for standardized scoring.

In the opening segment of this 6-part RX Review, experts discuss new USMSTF guidance on bowel preparation for colonoscopy.

Patients with celiac disease had a 2-fold greater risk of developing a chronic liver disease and experiencing major adverse liver outcomes.

Topline results from the phase 2b ANTHEM-UC study show all 3 doses of once-daily oral icotrokinra met the primary endpoint for clinical response.

The gastroenterology month in review spotlights GI FDA news, research about colorectal cancer and alcohol complications, and new data for mirikizumab.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2025.

In adolescents and young adults, gastrointestinal complications from alcohol are increasing at greater rates than other organ systems.

Amneal Pharmaceuticals launched mesalamine 800 mg delayed-release tablets for UC and received FDA approval for various lenalidomide doses for blood cancers.

Patients with adenomas had a greater risk of colorectal cancer, and advanced adenomas were linked to a greater risk of cancer-related and all-cause mortality.

Barnes explains the significance of having mirikizumab as a treatment option for Crohn’s disease and reviews new VIVID-2 open-label extension data.

The Fast Track Designation was granted to Biodexa Pharmaceuticals’ eRapa based on phase 2 data showing its safety and tolerability in adults with FAP.

Study findings suggest children with documented SARS-CoV-2 infection face an increased risk of GI tract symptoms than those without the infection.

Findings from the VIVID-2 open-label extension study in patients with CD highlight long-term clinical and endoscopic outcomes with mirikizumab.

This month in review spotlights HCPLive’s coverage of gastroenterology pipeline news, a feature about gastroparesis and migraine, and recent GI research.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.

The rolling NDA submission will include new data from the STARS Extend open-label extension study as well as data from the phase 3 STARS trial.

Gastroparesis during migraine attacks can hinder oral medication absorption. Migraine experts discuss the connection between gastroparesis and migraine.

MASLD and MetALD were linked to a greater risk of incident IBD, with risk increasing as the number of associated cardiometabolic risk factors increased.

The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation.

Dubinsky describes the evolution from anti-TNF therapies to IL-23 antagonists and the significance of mirikizumab’s approval for Crohn’s disease.